– FRANCE, Lyon – ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: FR0011471135 – ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces it has coopted Luc Dochez as new independent board member and will propose his appointment at the upcoming general assembly in June.

Luc Dochez, has served as Chief Business Officer and Senior Vice-President of Business Development of Prosensa (NASDAQ: RNA) since November 2008 until its recent acquisition by Biomarin. At Prosensa, Luc has been instrumental in signing a >$500M licensing deal with GSK, he has been actively involved in the successful listing on NASDAQ and he has managed the process leading to the acquisition of the company by BioMarin for $860M. Mr. Dochez has over 15 years of experience in the biotechnology industry. Before joining Prosensa, he was a consultant within Arthur D. Little’s biotechnology practice, Director of Business Development at Methexis Genomics, Vice President of Business Development at TiGenix N.V. and President of TiGenix Inc. Mr. Dochez holds a Pharm.D. degree from the University of Leuven , a postgraduate degree in business economics from the same university and an M.B.A. degree from Vlerick Management School.

“We are delighted and proud to have Luc Dochez joining our Board of Directors. His experience in business development and his extensive network, both in the pharmaceutical and financial communities, especially in the US, will be of great value to ERYTECH as we are entering a new phase of growth.” comments Gil Beyen, Chairman and CEO of ERYTECH.

The appointment of Luc Dochez as independent board member is effective immediately subject to final approval by the next general assembly.

About ERYTECH and ERY-ASP/GRASPA®

Created in Lyon in 2004, ERYTECH is a French biopharmaceutical company providing new prospects for cancer patients, particularly those with acute leukemia and selected solid tumors.

By encapsulating the asparaginase enzyme in red blood cells, ERYTECH has developed ERY-ASP/GRASPA®, an original treatment that targets cancer cells through “tumor starvation” while significantly reducing the side effects for patients. ERY-ASP/GRASPA® has recently announced positive Phase III data in Acute Lymphoblastic Leukemia (ALL) and is in Phase IIb clinical trial in Acute Myeloid Leukemia (AML) in Europe. The product is also in Phase I/II clinical development in ALL in the USA.

Every year about 50,000 patients are diagnosed with Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML), the two forms of acute leukemia. Today, for about 80% of these patients, mainly adults and relapsing patients, current forms of asparaginase cannot be used due to their toxicity. With a presumed improved safety profile, ERY-ASP/GRASPA® is being developed to allow all leukemia patients to be treated, even the most fragile ones, representing a market opportunity of more than EUR 1 billion.

The company is also developing other indications in solid tumors and certain orphan indications outside oncology. A Phase II study in pancreas cancer is ongoing and the company is exploring other solid tumor indications for ERY-ASP.

ERYTECH has obtained orphan drug designations for ERY-ASP/GRASPA® in ALL, AML and pancreas cancer, both in Europe and the USA, and has its own GMP-approved and operational manufacturing site in Lyon (France), and a site for clinical production in Philadelphia (USA).

The company has concluded licensing and distribution partnership agreements for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL with TEVA in Israel.

ERYTECH is listed on Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP – Compartment B) and is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. ERYTECH is also listed in the US under an ADR level 1 program (OTC, ticker EYRYY).

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Comments are closed.